Literature DB >> 7373082

Induction of resistance to Schistosoma mansoni by natural cord factor and synthetic lower homologues.

G R Olds, L Chedid, E Lederer, A A Mahmoud.   

Abstract

Resistance to schistosomiasis in mice can be acquired either specifically, by primary infection with Schistosoma mansoni, or nonspecifically, by treatment with a variety of unrelated agents such as bacille Calmette-Guérin. Several immunoadjuvants related to mycobacteria were examined for their ability to induce resistance to schistosomiasis. Natural cord factor (6,6'-trehalose dimycolate), a 100-carbon synthetic cord factor analogue, and dipalmitate trehalose induced significant protection. Trehalose dibehenate and muramyl dipeptide did not induce consistent protection. Since protection acquired by primary schistosomal infection or by any of these potentiating agents is partial, their possible additive effect was evaluated. The resistance of mice with schistosomiasis that were injected with trehalose dipalmitate and challenged with schistosomal cercariae was increased, as assayed by recovery of schistosomula from the lungs and of adult worms from the portal system. Thus, these synthetic adjuvants not only induce partial protection against schistosomiasis, but also significantly enhance acquired immunity in mice with primary infections.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7373082     DOI: 10.1093/infdis/141.4.473

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.

Authors:  Hong Yu; Xiaozhou Jiang; Caixia Shen; Karuna P Karunakaran; Janina Jiang; Nicole L Rosin; Robert C Brunham
Journal:  Infect Immun       Date:  2010-03-15       Impact factor: 3.441

2.  Induction of autophagy through CLEC4E in combination with TLR4: an innovative strategy to restrict the survival of Mycobacterium tuberculosis.

Authors:  Susanta Pahari; Shikha Negi; Mohammad Aqdas; Eusondia Arnett; Larry S Schlesinger; Javed N Agrewala
Journal:  Autophagy       Date:  2019-09-08       Impact factor: 16.016

3.  Vaccination of rabbits against Entamoeba histolytica with aqueous suspensions of trehalose-dimycolate as the adjuvant.

Authors:  A Sharma; A Haq; S Ahmad; E Lederer
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

Review 4.  A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.

Authors:  Yvonne Perrie; Elisabeth Kastner; Randip Kaur; Alexander Wilkinson; Andrew J Ingham
Journal:  Hum Vaccin Immunother       Date:  2013-04-12       Impact factor: 3.452

5.  Trehalose dimycolate enhances resistance to infection in neutropenic animals.

Authors:  G S Madonna; G D Ledney; T B Elliott; I Brook; J T Ulrich; K R Myers; M L Patchen; R I Walker
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

6.  Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines.

Authors:  L Holten-Andersen; T M Doherty; K S Korsholm; P Andersen
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

7.  [Suppression of the parasitemia in rodent filariasis (Litomosoides carinii) by immunization with BCG and microfilaria. II. Intravenous BCG application].

Authors:  P Kimmig
Journal:  Z Parasitenkd       Date:  1985

8.  Rapid Quantification and Validation of Lipid Concentrations within Liposomes.

Authors:  Carla B Roces; Elisabeth Kastner; Peter Stone; Deborah Lowry; Yvonne Perrie
Journal:  Pharmaceutics       Date:  2016-09-13       Impact factor: 6.321

Review 9.  Identification and Biological Activity of Synthetic Macrophage Inducible C-Type Lectin Ligands.

Authors:  Chriselle D Braganza; Thomas Teunissen; Mattie S M Timmer; Bridget L Stocker
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.